PSYCHOACTIVE DRUG SCREENING
PSYCHOACTIVE DRUG SCREENING
批准号:
2320817
负责人:
JOHN W FERKANY
金额:
$55.0万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-07-01 至 1995-06-30
中文摘要
NIMH筛查计划的建立是为了评估自然或
具有潜在中枢神经系统(CNS)活性的合成化合物
来自从事基础或临床前研究的个别科学家。
中枢活性天然产物提取物尤其令人感兴趣
以寻找新的药理作用机制。筛查成本为
费用由NIMH支付;调查人员不会受到任何指控。在这下面
合同,研究人员可以提交化合物在受体中进行评估-
基于可能预测心理治疗活动的化验。
这份合同的主要目的是帮助设计新的
治疗药物,以更好地预测和了解
潜在的副作用,并更好地了解
新药物的治疗作用。为了实现这些广泛的目标,
NIMH强烈鼓励调查人员跟进那些
显示活性(即抑制配体结合或酶活性)
通过额外的测试。其他测试可以包括,例如,
受体亚型、初步IC50、功能分析或体内试验
活动,并将视具体情况而定。NIMH预计
提交化合物的调查人员将:1)公布所获得的结果
从筛查分析(出版物应认可该服务
由NIMH程序提供);以及,2)向NIMH提供
已出版的手稿。
计划将从该程序生成的数据输入
到NIMH结构-活动数据库中。此信息将用作
帮助设计和发现新化合物的资源
在治疗精神健康障碍方面的潜在用途。
英文摘要
The NIMH Screening Program was established in order to evaluate natural or
synthetic compounds with potential central nervous system (CNS) activity
from individual scientists engaged in basic or preclinical research.
Centrally active natural product extracts are especially of interest in
order to search for novel pharmacologic mechanisms. Screening costs are
paid for by the NIMH; there are no charges to investigators. Under this
contract, investigators may submit compounds for evaluation in receptor-
based assays which may be predictive of psychotherapeutic activity.
The main purpose of this contract is to aid in the design of new
therapeutic agents, to better predict and understand mechanisms of
potential side-effects, and to better understand the mechanisms of
therapeutic action of new agents. In order to accomplish these broad aims,
the NIMH strongly encourages investigators to follow up compounds which
display activity (i.e., inhibition of ligand binding or enzyme activity)
with additional testing. Additional tests may include, for example,
receptor subtypes, preliminary IC50, functional assays, or in vivo
activity and will be determined on a case-by-case basis. The NIMH expects
that investigators submitting compounds will: 1) publish results obtained
from the screening analyses (publications should acknowledge the service
provided by the NIMH program); and, 2) provide the NIMH with a copy of the
published manuscript.
It is planned that the data generated from this program will be entered
into an NIMH structure-activity database. This information will serve as
a resource to assist in the design and discovery of novel compounds with
potential use in the treatment of mental health disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PSYCHOACTIVE DRUG SCREENING
-
批准号:2320822
-
项目类别:
-
资助金额:$45.0万
-
财政年份:1992
-
负责人:JOHN W FERKANY
-
依托单位:
PSYCHOACTIVE DRUG SCREENING
-
批准号:2875545
-
项目类别:
-
资助金额:$11.77万
-
财政年份:1992
-
负责人:JOHN W FERKANY
-
依托单位:
PSYCHOACTIVE DRUG SCREENING
-
批准号:2320816
-
项目类别:
-
资助金额:$60.0万
-
财政年份:1992
-
负责人:JOHN W FERKANY
-
依托单位:
PSYCHOACTIVE DRUG SCREENING
-
批准号:2875544
-
项目类别:
-
资助金额:$6.8万
-
财政年份:1992
-
负责人:JOHN W FERKANY
-
依托单位:
PSYCHOACTIVE DRUG SCREENING
-
批准号:2320821
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1992
-
负责人:JOHN W FERKANY
-
依托单位:
PSYCHOACTIVE DRUG SCREENING
-
批准号:2320815
-
项目类别:
-
资助金额:$7.0万
-
财政年份:1992
-
负责人:JOHN W FERKANY
-
依托单位:
PSYCHOACTIVE DRUG SCREENING
-
批准号:2320820
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1992
-
负责人:JOHN W FERKANY
-
依托单位:
GABAB RECEPTOR AGONISTS AND ANTAGONISTS
-
批准号:3504188
-
项目类别:
-
资助金额:$4.92万
-
财政年份:1988
-
负责人:JOHN W FERKANY
-
依托单位:
NONCOMPETITIVE NMDA RECEPTOR ANTAGONISTS
-
批准号:3504311
-
项目类别:
-
资助金额:$4.59万
-
财政年份:1988
-
负责人:JOHN W FERKANY
-
依托单位:
EXCITATORY AMINO ACID ANTAGONISTS AS ANTIEPILEPTIC DRUGS
-
批准号:3509110
-
项目类别:
-
资助金额:$17.92万
-
财政年份:1985
-
负责人:JOHN W FERKANY
-
依托单位:
国内基金
海外基金
登录
查看更多内容
不同功能基团的电中性Drug-Free纳米颗粒的构建及克服肿瘤耐药的研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:杨胜彩
-
依托单位:
Drug-ADR-Pathway复合网络构建及ADR分子机制研究
-
批准号:61372188
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:陈秀杰
-
依托单位:
Drug-pHLA对接指纹图谱库的构建及HLA介导SADR的预测方法研究
-
批准号:61073135
-
项目类别:面上项目
-
资助金额:10.0万元
-
批准年份:2010
-
负责人:梅虎
-
依托单位:
新型药物传输系统drug-LDHs 复合纳米粒子的可控制备及其微结构对缓控释性能的调控
-
批准号:20776012
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2007
-
负责人:张慧
-
依托单位:
用Drug-Western法分离恶性疟原虫cDNA编码的青蒿素类药物结合蛋白
-
批准号:30070681
-
项目类别:面上项目
-
资助金额:14.0万元
-
批准年份:2000
-
负责人:程远国
-
依托单位: